Diadem Announces New Publication Reviewing How Post Translational Modifications of p53 Variants May Contribute to Development of Alzheimer's Disease

MILAN, Sept. 23, 2021 /PRNewswire/ -- Diadem srl, a company developing the first blood-based test for the early prediction of progression to Alzheimer's disease (AD), today announced release of a new publication, Post-Translational Modifications of the p53 Protein and the Impact in...

from PR Newswire: https://ift.tt/39vD06e